Nifty
Sensex
:
:
11930.35
40685.50
33.90 (0.28%)
127.01 (0.31%)

Pharmaceuticals & Drugs - Domestic

Rating :
75/99

BSE: 539523 | NSE: ALKEM

2601.10
23-Oct-2020
  • Open
  • High
  • Low
  • Previous Close
  •  2629.00
  •  2641.45
  •  2591.00
  •  2618.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  69721
  •  1827.31
  •  3090.00
  •  1881.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 31,064.78
  • 22.78
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,673.42
  • 0.96%
  • 4.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 62.43%
  • 0.22%
  • 20.13%
  • FII
  • DII
  • Others
  • 3.92%
  • 12.49%
  • 0.81%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.31
  • 11.12
  • 9.29

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.79
  • 11.54
  • 7.87

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.32
  • 8.73
  • 21.34

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 28.75
  • 30.69

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 4.64
  • 4.61

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 20.05
  • 20.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
2,003.49
1,849.50
8.33%
2,048.99
1,854.20
10.51%
2,181.84
1,926.32
13.26%
2,264.03
1,918.90
17.99%
Expenses
1,470.31
1,585.00
-7.24%
1,745.96
1,619.19
7.83%
1,728.57
1,612.77
7.18%
1,811.44
1,555.23
16.47%
EBITDA
533.18
264.50
101.58%
303.03
235.01
28.94%
453.27
313.55
44.56%
452.59
363.67
24.45%
EBIDTM
26.61%
14.30%
14.01%
12.67%
20.77%
16.28%
19.99%
18.95%
Other Income
43.50
17.47
149.00%
27.47
27.66
-0.69%
27.86
7.58
267.55%
31.42
24.52
28.14%
Interest
17.10
16.12
6.08%
14.15
6.59
114.72%
17.04
15.38
10.79%
17.75
16.40
8.23%
Depreciation
66.83
55.83
19.70%
81.05
57.27
41.52%
59.48
47.69
24.72%
56.40
45.77
23.22%
PBT
492.75
210.02
134.62%
235.30
198.81
18.35%
404.61
258.06
56.79%
409.86
326.02
25.72%
Tax
69.56
22.73
206.03%
43.76
28.31
54.57%
14.65
52.61
-72.15%
29.34
65.60
-55.27%
PAT
423.19
187.29
125.95%
191.54
170.50
12.34%
389.96
205.45
89.81%
380.52
260.42
46.12%
PATM
21.12%
10.13%
7.11%
9.20%
17.87%
10.67%
16.81%
13.57%
EPS
35.38
15.66
125.93%
16.02
14.26
12.34%
32.61
17.18
89.81%
31.82
21.77
46.16%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
8,498.35
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
3,743.35
3,126.00
2,495.23
2,015.64
1,690.79
Net Sales Growth
12.58%
13.42%
15.10%
12.38%
15.49%
31.56%
19.75%
25.28%
23.79%
19.21%
 
Cost Of Goods Sold
7,116.69
2,959.14
2,602.77
1,986.45
1,807.71
1,630.87
1,453.41
1,168.05
866.74
645.76
597.04
Gross Profit
1,381.66
5,385.22
4,754.42
4,405.39
3,879.82
3,293.97
2,289.94
1,957.95
1,628.49
1,369.88
1,093.75
GP Margin
16.26%
64.54%
64.62%
68.92%
68.22%
66.88%
61.17%
62.63%
65.26%
67.96%
64.69%
Total Expenditure
6,756.28
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
3,321.52
2,716.05
2,132.78
1,640.43
1,404.20
Power & Fuel Cost
-
130.14
121.48
112.64
86.34
66.33
53.31
60.33
53.17
50.68
37.78
% Of Sales
-
1.56%
1.65%
1.76%
1.52%
1.35%
1.42%
1.93%
2.13%
2.51%
2.23%
Employee Cost
-
1,505.49
1,362.46
1,191.64
1,003.85
861.08
645.87
531.56
412.29
303.45
267.09
% Of Sales
-
18.04%
18.52%
18.64%
17.65%
17.48%
17.25%
17.00%
16.52%
15.05%
15.80%
Manufacturing Exp.
-
765.43
806.17
838.87
692.26
550.16
367.58
305.99
264.84
234.61
195.99
% Of Sales
-
9.17%
10.96%
13.12%
12.17%
11.17%
9.82%
9.79%
10.61%
11.64%
11.59%
General & Admin Exp.
-
525.62
512.52
469.90
377.69
331.27
238.45
184.73
180.17
139.46
106.32
% Of Sales
-
6.30%
6.97%
7.35%
6.64%
6.73%
6.37%
5.91%
7.22%
6.92%
6.29%
Selling & Distn. Exp.
-
854.48
726.21
675.43
596.44
503.69
434.56
367.31
295.39
226.31
167.01
% Of Sales
-
10.24%
9.87%
10.57%
10.49%
10.23%
11.61%
11.75%
11.84%
11.23%
9.88%
Miscellaneous Exp.
-
130.67
110.81
107.99
124.29
128.19
128.34
98.08
60.18
40.16
167.01
% Of Sales
-
1.57%
1.51%
1.69%
2.19%
2.60%
3.43%
3.14%
2.41%
1.99%
1.95%
EBITDA
1,742.07
1,473.39
1,114.77
1,008.92
998.95
853.25
421.83
409.95
362.45
375.21
286.59
EBITDA Margin
20.50%
17.66%
15.15%
15.78%
17.56%
17.33%
11.27%
13.11%
14.53%
18.61%
16.95%
Other Income
130.25
104.22
87.70
115.42
112.01
239.71
181.04
165.35
167.17
145.28
113.42
Interest
66.04
65.06
54.63
55.33
45.16
71.24
81.11
93.08
88.23
58.10
41.23
Depreciation
263.76
252.76
193.18
143.03
101.17
93.31
70.94
52.26
39.79
29.03
27.43
PBT
1,542.52
1,259.79
954.66
925.98
964.63
928.41
450.82
429.96
401.60
433.36
331.35
Tax
157.31
110.48
181.02
287.56
59.96
176.18
59.23
-5.36
17.97
27.52
35.57
Tax Rate
10.20%
8.77%
18.96%
31.05%
6.22%
18.98%
13.14%
-1.25%
4.47%
6.35%
10.73%
PAT
1,385.21
1,127.07
760.51
630.94
892.03
741.59
391.59
435.32
383.82
406.54
295.59
PAT before Minority Interest
1,366.38
1,149.31
773.64
638.42
904.67
752.23
391.59
435.32
383.63
405.84
295.78
Minority Interest
-18.83
-22.24
-13.13
-7.48
-12.64
-10.64
0.00
0.00
0.19
0.70
-0.19
PAT Margin
16.30%
13.51%
10.34%
9.87%
15.68%
15.06%
10.46%
13.93%
15.38%
20.17%
17.48%
PAT Growth
68.18%
48.20%
20.54%
-29.27%
20.29%
89.38%
-10.05%
13.42%
-5.59%
37.54%
 
EPS
115.82
94.24
63.59
52.75
74.58
62.01
32.74
36.40
32.09
33.99
24.71

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
3,002.63
2,584.97
2,177.31
1,820.05
1,433.69
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
11.96
11.96
11.96
11.96
Total Reserves
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
2,978.72
2,573.01
2,165.35
1,808.09
1,421.73
Non-Current Liabilities
-541.52
-288.92
-358.61
-400.78
-306.15
197.02
323.92
361.67
524.89
434.40
Secured Loans
148.93
219.80
122.12
175.01
112.49
33.43
232.25
255.57
308.97
246.26
Unsecured Loans
10.31
11.50
8.61
6.55
10.97
0.00
0.00
0.02
0.00
0.00
Long Term Provisions
222.04
173.72
150.27
102.17
82.96
66.58
42.29
44.30
179.99
162.14
Current Liabilities
3,243.31
2,217.53
2,383.31
1,689.69
1,537.60
2,005.98
1,402.58
1,731.80
1,120.59
981.86
Trade Payables
954.05
962.25
960.71
741.37
580.48
465.93
305.73
287.59
276.03
167.69
Other Current Liabilities
555.47
428.08
520.04
339.25
366.01
327.06
201.28
187.74
111.47
87.39
Short Term Borrowings
1,503.51
671.27
761.27
472.37
464.17
1,128.57
845.22
1,210.17
670.31
663.10
Short Term Provisions
230.28
155.93
141.29
136.70
126.94
84.42
50.35
46.30
62.78
63.68
Total Liabilities
9,010.76
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
4,270.78
3,465.72
2,851.77
Net Block
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
1,374.34
1,170.01
1,072.12
919.17
692.73
Gross Block
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
1,744.89
1,170.01
1,072.12
919.17
692.73
Accumulated Depreciation
698.94
495.64
320.19
180.16
89.10
370.55
0.00
0.00
0.00
0.00
Non Current Assets
3,514.73
3,284.43
2,996.80
2,954.64
2,249.73
2,953.23
2,709.33
2,114.56
2,153.43
1,313.22
Capital Work in Progress
362.97
492.96
380.97
299.26
172.42
110.69
0.00
0.00
0.00
0.00
Non Current Investment
91.50
95.74
98.45
259.44
234.39
419.73
338.24
410.33
298.91
6.10
Long Term Loans & Adv.
105.57
118.64
141.37
193.07
142.35
542.17
418.40
339.39
258.82
153.98
Other Non Current Assets
46.68
46.65
92.42
405.83
251.03
506.30
782.68
292.72
676.53
460.41
Current Assets
5,496.03
4,216.13
4,013.22
2,917.14
2,768.70
2,338.05
1,602.14
2,156.22
1,312.29
1,538.55
Current Investments
169.89
227.88
345.82
293.56
274.18
61.05
249.77
67.31
23.78
47.70
Inventories
1,818.82
1,499.87
1,442.19
1,206.00
909.37
784.23
620.33
553.96
384.92
250.87
Sundry Debtors
1,649.36
1,248.41
1,080.50
713.64
567.51
527.08
366.93
318.21
246.61
171.02
Cash & Bank
1,092.21
661.60
576.78
399.26
780.90
790.76
206.29
995.45
513.81
989.82
Other Current Assets
765.75
173.37
177.30
133.33
236.74
174.93
158.82
221.29
143.17
79.14
Short Term Loans & Adv.
482.24
405.00
390.63
171.35
141.30
114.85
110.04
115.29
80.24
40.32
Net Current Assets
2,252.72
1,998.60
1,629.91
1,227.45
1,231.10
332.07
199.56
424.42
191.70
0.00
Total Assets
9,010.76
7,500.56
7,010.02
5,871.78
5,018.43
5,291.28
4,311.47
4,270.78
3,465.72
2,851.77

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
585.08
779.65
266.04
471.14
725.83
328.14
290.01
78.05
159.05
147.93
PBT
1,259.79
954.66
925.98
964.63
928.41
514.16
429.96
401.60
433.36
331.35
Adjustment
255.87
216.37
116.47
33.02
-14.42
15.89
7.48
-30.64
-32.93
-17.61
Changes in Working Capital
-647.20
-140.27
-573.24
-262.55
10.05
-96.27
-36.37
-182.68
-144.78
-99.22
Cash after chg. in Working capital
868.46
1,030.76
469.21
735.10
924.04
433.78
401.07
188.28
255.65
214.52
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-283.38
-251.11
-203.17
-263.96
-198.21
-105.64
-111.06
-110.23
-96.60
-66.59
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-741.35
-316.39
-357.23
-285.93
202.27
-237.00
350.44
-403.52
-247.50
-822.79
Net Fixed Assets
-310.63
-342.15
-531.27
-390.07
160.79
-111.90
-103.11
-213.73
-206.97
Net Investments
-260.44
-151.10
-26.86
-359.97
-87.11
-129.77
-361.40
-207.20
-318.96
Others
-170.28
176.86
200.90
464.11
128.59
4.67
814.95
17.41
278.43
Cash from Financing Activity
79.15
-378.94
84.56
-137.88
-927.27
-51.79
-599.94
355.64
-11.07
778.87
Net Cash Inflow / Outflow
-77.12
84.32
-6.63
47.33
0.83
39.35
40.51
30.17
-99.52
104.01
Opening Cash & Equivalents
249.05
166.71
166.63
127.03
123.75
100.82
57.31
26.35
123.96
19.98
Closing Cash & Equivalent
175.94
249.05
166.71
166.63
127.05
139.60
100.82
57.31
26.35
123.96

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
515.21
454.86
406.76
373.67
308.82
251.16
216.13
182.05
152.18
0.00
ROA
13.92%
10.66%
9.91%
16.61%
14.59%
8.16%
10.14%
9.92%
12.85%
10.37%
ROE
19.82%
15.02%
13.69%
22.18%
22.47%
14.02%
18.28%
19.19%
24.95%
20.63%
ROCE
18.60%
16.49%
17.86%
21.31%
23.09%
13.26%
14.06%
14.96%
19.02%
15.90%
Fixed Asset Turnover
3.74
3.80
3.75
3.33
3.07
2.65
2.89
2.59
2.57
2.49
Receivable days
42.66
39.69
38.15
39.95
39.57
42.27
38.62
40.02
36.80
36.14
Inventory Days
48.86
50.14
56.31
65.96
61.23
66.41
66.19
66.53
56.02
53.01
Payable days
52.06
60.17
61.04
52.36
49.96
45.83
42.61
49.36
50.29
47.05
Cash Conversion Cycle
39.46
29.66
33.42
53.55
50.84
62.85
62.19
57.20
42.53
42.10
Total Debt/Equity
0.28
0.17
0.21
0.15
0.18
0.43
0.44
0.71
0.55
0.00
Interest Cover
20.36
18.48
17.74
22.36
14.03
6.56
5.62
5.55
8.46
9.04

News Update:


  • Alkem Laboratories - Quarterly Results
    7th Aug 2020, 13:38 PM

    Read More
  • Alkem Laboratories launches Favipiravir for COVID-19 treatment
    6th Aug 2020, 09:12 AM

    The company has launched Favipiravir under the brand name ‘Alfluenza’ in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.